nivolumab,ipilimumab,cabozantinib
bms,ipsen
['nivolumab', 'ipi/', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'cabopoint', 'ipilimumab', 'cabo ', 'nivo']
cabopoint interim analysis: 2l cabo post-1l cpi combo (ipi/nivo or cpi/vegfr-targeted) in ccrcc cohort a (prior ipi/nivo): 31.7% cohort b (prior cpi/vegfr): 25% 1 cr, 25 pr final analysis pending sep 2023. ae data pending
#gu23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @AUB_Lebanon and @MCG_Urology